“Dear Doctor” Letter About Invokana And Amputations Was Sent In Canada
In September 2017 Health Canada required Janssen, the drug company responsible for Invokana and Invokamet, to send a Dear Healthcare Professional Letter — commonly referred to as a “Dear Doctor” letter...
View ArticleInvokana – Amputations: No Explanation Yet As Regards “How” And “Why”
What still is not clear to drug regulators and medical researchers about the drug safety issue of lower limb amputations linked to Invokana and Invokamet use is the so-called “mechanism of injury”. Put...
View ArticleNew Analysis Finds An Increased Risk Of Bladder Cancer For Jardiance
This article, “SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials”, was published in the October 2017 edition of Diabetologia....
View ArticleJardiance – Lower Limb Amputations Drug Safety Issue Remains Uncertain
It appears there needs to more medical research done on the risk of lower limb amputations for patients who use the increasing popular diabetes medicines in the sodium glucose cotransporter 2 (SGLT2)...
View ArticleInvokana, Jardiance, And Farxiga Have Increased Risks Of Amputations
Sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors) such as Invokana, Jardiance, and Farxiga have a higher risk of leg, feet, and toe amputations drug-class side effect when compared to older...
View ArticleIncreased Risks Of Lower-Limb Amputations For Farxiga And Jardiance
During late August a presentation at the 2018 European Society of Cardiology Congress in Munich, Germany included evidence that the SGLT-2 inhibitors Invokana, Jardiance, and Farxiga all are associated...
View ArticleInvokana / Jardiance / Farxiga: Increased Risk Of Pancreatitis, According To...
Health Canada’s safety review of sodium-glucose cotransporter-2 (SGLT2) inhibitors — e.g., Invokana (canagliflozin), Farxiga (dapagliflozin), and Jardiance (empagliflozin) — concluded in July 2018 with...
View ArticleFournier’s Gangrene: Side Effect For Invokana, Farxiga, And Jardiance
From this August 29, 2018 Drug Safety Communication, “FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes”, we get the following details about...
View ArticleAmputations Are Diabetes Drugs Side Effects For SGLT2 Inhibitors Class
There seems to be an increasing degree of acknowledgement in the medical literature that these lower limb amputations are drug-class side effects of SGLT2 inhibitor diabetes medicines such as Jardiance...
View ArticleFarxiga And Jardiance Have Two-Time Increased Risk For Amputations
Patients using the diabetes drugs Farxiga and Jardiance had twice the risk for lower limb amputations relative to certain other diabetes medicines, according to a new observational study published in...
View ArticleLower Limb Amputations From All SGLT2 Inhibitors, or Just Invokana?
A “Black-Box Warning” about the increased risk of lower limb amputations was added to the drug labels for Invokana and Invokamet in July 2017. Since that time there has been a mix of opinions expressed...
View ArticleCases Of Fournier Gangrene Associated With Diabetes Drugs Invokana,...
The FDA has identified 55 unique cases of Fournier gangrene associated with diabetes drugs in the Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors class between March 1, 2013 and January 31, 2019. Of...
View ArticleQuestions Raised About Whether Fournier’s Gangrene Is A Side Effect Of...
At the recent American Diabetes Association (ADA) Scientific Sessions there were reportedly questions raised about whether there is an increased risk of Fournier’s gangrene when using Farxiga as well...
View ArticleJardiance – Lower Limb Amputations Drug Safety Issue Remains Uncertain
It appears there needs to more medical research done on the risk of lower limb amputations for patients who use the increasing popular diabetes medicines in the sodium glucose cotransporter 2 (SGLT2)...
View ArticleInvokana, Jardiance, And Farxiga Have Increased Risks Of Amputations
Sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors) such as Invokana, Jardiance, and Farxiga have a higher risk of leg, feet, and toe amputations drug-class side effect when compared to older...
View ArticleIncreased Risks Of Lower-Limb Amputations For Farxiga And Jardiance
During late August a presentation at the 2018 European Society of Cardiology Congress in Munich, Germany included evidence that the SGLT-2 inhibitors Invokana, Jardiance, and Farxiga all are associated...
View ArticleInvokana / Jardiance / Farxiga: Increased Risk Of Pancreatitis, According To...
Health Canada’s safety review of sodium-glucose cotransporter-2 (SGLT2) inhibitors — e.g., Invokana (canagliflozin), Farxiga (dapagliflozin), and Jardiance (empagliflozin) — concluded in July 2018 with...
View ArticleFournier’s Gangrene: Side Effect For Invokana, Farxiga, And Jardiance
From this August 29, 2018 Drug Safety Communication, “FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes”, we get the following details about...
View ArticleAmputations Are Diabetes Drugs Side Effects For SGLT2 Inhibitors Class
There seems to be an increasing degree of acknowledgement in the medical literature that these lower limb amputations are drug-class side effects of SGLT2 inhibitor diabetes medicines such as Jardiance...
View ArticleFarxiga And Jardiance Have Two-Time Increased Risk For Amputations
Patients using the diabetes drugs Farxiga and Jardiance had twice the risk for lower limb amputations relative to certain other diabetes medicines, according to a new observational study published in...
View Article